1. The presence of valve and vascular calcification (VC) should be investigated annually in patients with CKD G3a-5D by means of radiological examinations (lateral abdominal or pelvic and hand radiographs) and echocardiography, respectively (Opinion).

2. CKD G3a-5D patients with known vascular and/or valve calcification should be considered at high cardiovascular risk (Evidence), and this information is valid to guide the treatment of CKD-MBD (Opinion).

RATIONAL

Cardiovascular diseases (CVD) are the leading cause of mortality in patients with chronic kidney disease (CKD)\(^1\). Valve and vascular calcifications (VC) are among the most frequent complications of CKD, being one of the components of mineral and bone disorder in CKD (CKD-MBD)\(^2\). The prevalence of VC increases with CKD progression, and may be present in more than 30% of patients under conservative treatment\(^3,4\) and in more than 80% of those on dialysis\(^5,6\). Valve calcification is also common and it is observed in about 20% to 25% of CKD patients undergoing conservative treatment\(^7\) and between 32% to 76% of patients on dialysis\(^8,9\).

There are several risk factors for VC development and progression in CKD, including traditional risk factors such as advanced age, presence of diabetes mellitus, systemic arterial hypertension, dyslipidemia, smoking, and obesity, and risk factors associated with the kidney disease itself. VC could be present in both the intima and media layers of arteries\(^10\). The calcification located in the intima of the vessel is typically secondary to systemic inflammation and established atherosclerosis\(^11\). CKD patients, especially those on dialysis, have a chronic inflammatory state that is an important contributor to endothelial cell damage and accelerated progression of atherosclerotic plaque\(^10,12\). On the other hand, VC located in the media layer of the vessel is associated with CKD-MBD, being an active process of vessel “ossification” linked to an imbalance between inhibitor and promoter factors of calcification\(^10,13,14\) (Table 1). In the presence of calcium (Ca), phosphorus (P) and uremic toxins overload, the vascular smooth muscle cells undergo a phenotypic transformation and acquire characteristics of osteoblastic cells, producing bone matrix inside the vascular wall\(^10,15\). A study demonstrates that elevated PTH levels may also play a role in the pathophysiology of VC\(^16\). Valve calcification in CKD patients, in turn, is also related to CKD-MBD, inflammation, oxidative stress, and pressure and volume overload\(^17\).
Defining the exact prognostic value of VC is complex in CKD patients due to the difficulty in discriminating the histological type, whether in the intima or media layer, and the pathophysiological mechanisms of calcification, which are distinct in relation to the general population. However, the loss of vessel elasticity, myocardial ischemia and fibrosis caused by VC in CKD lead to increased mortality and higher risk of cardiovascular events. Valve calcification, on the other hand, contributes to increased afterload, worsening left ventricular hypertrophy and myocardial fiber disarray. The end product of vascular, valve, and myocardial changes is increased risk of arrhythmias, heart failure, and sudden death. The absence of VC, in general, is associated with good prognosis.

Although, to date, there is no specific therapy capable of regressing calcification, an annual investigation is recommended in order to identify patients at increased cardiovascular risk. Diagnosis of VC and valve calcification should be easy to perform and interpret, accurate, reproducible, safe, and cost-effective. Several methods have been used to detect and quantify valve and VC, but none of them could be considered optimal. In addition, methods to assess VC are usually not able to differentiate its location, whether in the intima or the media layer. The currently available methods could be classified as qualitative, semiquantitative and quantitative.

### A. Qualitative

**A.1 Plain radiography**: accessible method, as it is easy to obtain and has a low cost, which allows detecting the presence of VC in vessels of different body segments. However, it has low sensitivity and it is unable of quantifying the severity of VC.

**A.2 Arterial ultrasound**: qualitative method that allows the assessment of VC presence in common carotid arteries, abdominal aorta and iliac-femoral arteries. Although it is a safe and relatively low-cost method, ultrasound has the disadvantage of being operator dependent. The presence of VC assessed by this method was associated with cardiovascular mortality in CKD patients. Furthermore, one study suggested that measuring the carotid arteries intima-media thickness could identify not only the presence but also the progression of VC. However, studies are still limited in this population.

**A.3 Echocardiogram**: safe, reliable, and accessible exam capable of detecting calcification and mitral and aortic valve stenosis, with the additional benefit of

| Promoters | Inhibitors |
|-----------|------------|
| BMP-2, 4 and 6 | Matrix Gla Protein |
| Osteocalcin | Osteopontin |
| Bone Sialoprotein | Osteoprotegerin |
| Alkaline phosphatase | Fetuin A |
| Calcium and phosphorus | Klotho |
| Oxidative Stress | Pyrophosphate |
| Inflammatory cytokines | Carbonic anhydride |
| Diabetes | BMP-7 |
| Dyslipidemia | Vitamin K |
| Coumarins | Magnesium |
| Matrix exosomes | Sodium thiosulfate |
| Apoptotic cells | BMP-7 |
| MMP2, 3 and 7 | Osteoprotegerin |
| Runx2 | Osteoprotegerin |
| Sox9 | Osteoprotegerin |
| Osterix/Sp7 | Osteoprotegerin |

BMP: Bone morphogenetic protein; MMP: Matrix metalloproteinases; Runx2, Sox9 and Osterix: Osteochondrogenic transcription factors.
early diagnosis of changes in cardiac function. It has the advantage of not requiring the use of iodinated or gadolinium contrast, which should be avoided in the CKD population17.

B. SEMIQUANTITATIVE

B.1 Lateral lumbar spine radiography: the best semiquantitative method was described by Kauppila et al. based on calcification foci number and extent in the aortic segments at the level of the first to the fourth lumbar vertebrae, applying a score from 0-2428. This score showed good correlation with coronary calcification detected by computed tomography and it was also associated with mortality and cardiovascular events in dialysis patients29,30. The use of this tool could help in the risk stratification of this population.

B.2 Hand and pelvis radiographs: simple, available, low-cost, and easy-to-interpret method for VC assessment; it consists of dividing hand and pelvis radiographs into quadrants. The final score is the sum of the quadrants with calcification, ranging from 0 to 831. This method showed a significant correlation with coronary calcification and mortality in CKD patients32.

C. QUANTITATIVE

C.1 Coronary electron-beam computed tomography or multislice computed tomography: non-invasive techniques with low radiation exposure and no need to use contrast, being considered the gold standard for presence and quantification of VC. When performed in different periods, they allow the analysis of calcification progression24. Presence of calcium in the coronary artery is quantified by the Agatston score, which is calculated by multiplying the plaque area by a density coefficient (measured in Hounsfield units) and the result is given by summing the score of each coronary lesion. This method does not allow the distinction between calcification of the intima and media layers33. Studies show that coronary tomography has a prognostic role, since the presence and progression of VC are associated with cardiovascular complications and all-cause mortality in hemodialysis patients10,34,35.

It is important to note that, to date, there is no specific therapy for VC regression and it is unclear how reducing its speed of progression impacts the outcomes of CKD patients. The recommendation to perform annual plain abdominal radiography to detect VC and echocardiogram to detect valve calcification and cardiac functional assessment has as main objectives assessing the mortality risk and implementing measures that may delay the progression of VC. In this sense, the positivity of any of these tests points to an increased cardiovascular risk of the patient, impacting on the individualization and intensification of the management of modifiable risk factors22,31. As for the calcification quantification, it is not usually performed routinely, since CT scans are expensive and expose the patient to radiation. However, it can be considered in cases of positive qualitative tests, with the purpose of better prognostic stratification, especially in situations of research10,14.

REFERENCES

1. United States Renal Data System. Morbidity and Mortality in Patients with CKD. In: 2018 USRDS Annual data report: Epidemiology of kidney disease. Bethesda, MD; 2018.
2. Kidney International Supplements. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017 Jul;7(1):1–59.
3. Lamprea-Monteforte JA, McClellan RL, Astor BC, Matsushita K, Shlipak M, de Boer IH, et al. Chronic kidney disease, plasma lipoproteins, and coronary artery calcium incidence: the Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2013 Mar;33(3):652-8. https://doi.org/10.1161/ATVBAHA.112.300624
4. Chiu Y-W, Adler SG, Budoff MJ, Takasu J, Ashai J, Mehrotra R. Coronary artery calcification and mortality in diabetic patients with proteinuria. Kidney Int. 2010 Jun 2;77(12):P1107-14. https://doi.org/10.1038/ki.2010.70
5. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation. 2002 Jul 2;106(1):100-5. https://doi.org/10.1161/01. cir.0000020222.63035.c0
6. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000 May 18;342(20):1478-83. https://doi.org/10.1056/NEJM200005183422003
7. Ix JH, Shlipak MG, Katz R, Budoff MJ, Shavelle DM, Probstfield JL, et al. Kidney function and aortic valve and mitral annular calcification in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis. 2007 Sep 1;50(3):P412–20. https://doi.org/10.1053/j.ajkd.2007.05.020
8. Wang AY-M, Wang M, Woo J, Lam CW-K, Li PK-T, Lui S-F, et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol. 2003 Jan;14(1):159–68. https://doi.org/10.1097/01.ASN.0000038685.95946.83
9. Matsuo H, Dohi K, Machida H, Takeuchi H, Aoki T, Nishimura H, et al. Echocardiographic assessment of cardiac structural and functional abnormalities in patients with end-stage renal disease receiving chronic hemodialysis. Circ J. 2018 Jan 25;82(2):586-95. https://doi.org/10.1253/circj.CJ-17-0393
10. Vermeer M, Cozzolino M. Vascular calcification in chronic kidney disease: different bricks in the wall? Kidney Int. 2017 Apr 1;91(4):P808-17. https://doi.org/10.1016/j.kint.2016.09.024
23. Moody WE, Edwards NC, Chue CD, Ferro CJ, Townend JN. Arterial disease in chronic kidney disease. Heart. 2013 Mar;99(6):365-72. https://doi.org/10.1136/heartjnl-2012-302818

24. Karohl C, Gascon LD’M, Raggi P. Noninvasive imaging for assessment of calcification in chronic kidney disease. Nat Rev Nephrol. 2011 Aug 23;7(10):567-77. https://doi.org/10.1038/nrneph.2011.110

25. de Carvalho AB. Diretrizes Brasileiras de Prática Clínica para o Distúrbio Mineral e Ósseo na Doença Renal Crônica. J Bras Nefrol. 2011 Apr-Jun;33(1 Suppl 2):191.

26. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in endstage kidney disease. Hypertension. 2001 Oct 1;38(4):938-42. https://doi.org/10.1161/01.HYP.38.4.938

27. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO Clinical practice guidelines for diagnosis, evaluation, prevention and treatment of chronic kidney disease mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009 Aug 1;76(Suppl 115):S1-130. https://doi.org/10.1038/kands.2009.188

28. Kaupila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis. 1997 Jul 25;132(2):245-50. https://doi.org/10.1016/S0021-9150(97)00106-8

29. Bellasi A, Ferramosca E, Muntrer P, Ratti C, Wildman RP, Block GA, et al. Correlation of simple imaging tests and coronary artery calcium measured by computed tomography in hemodialysis patients. Kidney Int. 2006 Nov 1;70(9):P1623-8. https://doi.org/10.1038/sj.ki.5001820

30. Verbeke F, Van Biesen W, Honkanen E, Wikström B, Jensen PB, Krzesinski JM, et al. Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the calcification outcome in renal disease (CORD) study. Clin J Am Soc Nephrol. 2011 Jan;6(1):153-9. https://doi.org/10.2215/CJN.05120610

31. Adragão T, Pires A, Birne R, Curto JD, Lucas C, Gonçalves M, et al. A simple vascular calcification score predicts cardiovascular events and mortality in dialysis patients. Atherosclerosis. 2004 Jun 19;16(6):1480-8. https://doi.org/10.1016/j.atherosclerosis.2016.03.034

32. Adragão T, Pires A, Birne R, Curto JD, Lucas C, Gonçalves M, et al. A plain X-ray vascular calcification score is associated with arterial stiffness and mortality in dialysis patients. Nephrol Dial Transplant. 2009 Mar;24(3):997-1002. https://doi.org/10.1093/ndt/gfn384

33. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr M, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990 Mar 15;15(4):827-32. https://doi.org/10.1016/0735-1097(90)90282-t

34. Bellasi A, Ferramosca E, Ratti C, Block GA, et al. The density of calcified plaques and the volume of calcium predict mortality in hemodialysis patients. Clin J Am Soc Nephrol. 2011 Aug 23;7(10):1392-4. https://doi.org/10.1038/nsrnpb.2011.110

35. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007 Mar 1;71(5):P438-41. https://doi.org/10.1038/sj.ki.5002059